Viridian Therapeutics, Inc.\DE (VRDN) Current Assets (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Current Assets history runs 14 years deep, the most recent figure standing at $784.7 million for Q1 2026.

• On a quarterly basis, Current Assets rose 19.4% year-over-year to $784.7 million in Q1 2026; TTM through Mar 2026 was $784.7 million, a 19.4% increase from a year earlier, with the FY2025 full-year figure at $894.2 million, up 21.09% from the prior year.
• Current Assets declined to $784.7 million in Q1 2026 per VRDN's latest filing, from $894.2 million in the prior quarter.
• Across five years, Current Assets topped out at $894.2 million in Q4 2025 and bottomed at $166.2 million in Q2 2022.
• The 5-year median for Current Assets is $571.9 million (2025), against an average of $526.7 million.
• Across the five-year window, Current Assets dropped 25.96% in 2023 and soared 136.96% in 2024, its largest moves.
• Year by year, Current Assets stood at $431.2 million in 2022, then advanced by 12.83% to $486.5 million in 2023, then soared by 51.8% to $738.5 million in 2024, then gained by 21.09% to $894.2 million in 2025, then slipped by 12.24% to $784.7 million in 2026.
• Per Business Quant, the three latest VRDN Current Assets figures stand at $784.7 million (Q1 2026), $894.2 million (Q4 2025), and $571.9 million (Q3 2025).